Stock BIO BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Real-time Estimate Cboe BZX
Other stock markets
 03:34:07 2024-04-19 pm EDT 		5-day change 1st Jan Change
279.5 USD -0.53% Intraday chart for Bio-Rad Laboratories, Inc. -7.20% -13.65%
Apr. 15 Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT
Apr. 11 Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BU
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322
MT
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
AQ
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
AQ
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay
CI
Bio-Rad Laboratories COO Andrew Last to Retire in September
MT
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
BU
Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire
CI
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating
MT
North American Morning Briefing : Focus Turns to -2-
DJ
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400
MT
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center
MT
Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO
MT
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
BU
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as Chief Financial Officer, Effective April 15, 2024
CI
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024
CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM
Bio-rad Laboratories Insider Sold Shares Worth $1,008,000, According to a Recent SEC Filing
MT
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
BU
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. News Bio-Rad Laboratories, Inc.